Efficacy and safety of efgartigimod PH20 SC for Sjögren’s disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study)

Authors

Julie Jacobs (ORCID: https://orcid.org/0000-0003-2873-3364)
H. Yamamoto
Yushiro Endo (ORCID: https://orcid.org/0000-0002-7008-2334)
Tomohiro Koga (ORCID: https://orcid.org/0000-0003-2077-4428)
Sawana Narita
Yukinori Takagi (ORCID: https://orcid.org/0000-0002-9031-1253)
Yuri Fukushige
Tomoya Sakai (ORCID: https://orcid.org/0000-0003-3510-0979)
T. Shimizu
Naoki Hosogaya (ORCID: https://orcid.org/0000-0002-3229-2277)
Yuya Imai
Atsushi Kawakami
Misa Sumi
William Reiss

Institutions

University of Nagasaki (JP)
Argenx (Belgium) (BE)
Nagasaki University Hospital (JP)
Nagasaki University (JP)

Publication Details

Journal: Frontiers in Medicine
Published: 2026-01-02
DOI: https://doi.org/10.3389/fmed.2025.1719757
Primary Topic: Salivary Gland Disorders and Functions
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Argenx

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of efgartigimod PH20 SC for Sjögren’s disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study)

Julie Jacobs, H. Yamamoto, Yushiro Endo, Tomohiro Koga et al.

Jan 2, 2026

Frontiers in Medicine

Salivary Gland Disorders and Functions

article

Efficacy and safety of efgartigimod PH20 SC for Sjögren’s disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study)

Julie Jacobs, H. Yamamoto, Yushiro Endo, Tomohiro Koga, Sawana Narita, Yukinori Takagi, Yuri Fukushige, Tomoya Sakai, T. Shimizu, Naoki Hosogaya, Yuya Imai, Atsushi Kawakami, Misa Sumi, William Reiss

January 2, 2026article en

Abstract

No abstract available for this paper.

Frontiers in MedicineVol. 12

University of Nagasaki (JP), Argenx (Belgium) (BE), Nagasaki University Hospital (JP), Nagasaki University (JP)

Argenx

Openalex Percentile: Top 99%

Salivary Gland Disorders and Functions

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of efgartigimod PH20 SC for Sjögren’s disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study) — Julie Jacobs, H. Yamamoto, et al. · Frontiers in Medicine (2026) | TGRS Research Map | TGRS